BH-30643 is an OMNI-EGFR inhibitor that targets classical, atypical, and compound EGFR mutations and acquired resistance mutations in HER2.

and the remaining 10% of mutations involve exon 18 and 20. EGFR kinase domain mutations hyperactivate the kinase and confer a dependence on the mutated kinase for the survival of the NSCLC tumour ...

and human epidermal growth factor receptor 2 (HER2) genes. These mutations commonly occur in non-small cell lung cancer (NSCLC). More specifically, it aims to treat exon 20 mutations and other ...

Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to the ...

BAY 2927088, which combines inhibition of HER2 (including exon 20 insertions and point mutations) with blockade of EGFR, both mutations that are seen in NSCLC tumours. The oral drug was awarded ...

Sunvozertinib received FDA priority review for NSCLC with EGFR exon 20 insertion mutations after platinum-based chemotherapy progression. The WU-KONG1 Part B study showed a 53.3% objective response ...